Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AU565 | HER2amp | Luminal | Mebendazole | 13.3 | uM | 13030.174 | 0.5128 | -0.0788 | 0.8615 | |||
| AU565 | HER2amp | Luminal | Mebendazole | 66.7 | uM | 13030.174 | 0.2036 | -0.6848 | 0.8615 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 0.000171 | uM | 13579.174 | 0.9753 | 0.9387 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 0.000853 | uM | 13579.174 | 0.9555 | 0.8897 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 0.00427 | uM | 13579.174 | 0.9923 | 0.9808 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 0.0213 | uM | 13579.174 | 0.9391 | 0.8492 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 0.107 | uM | 13579.174 | 1.0031 | 1.0078 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 0.533 | uM | 13579.174 | 0.8143 | 0.5479 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 2.67 | uM | 13579.174 | 0.4758 | -0.2081 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 13.3 | uM | 13579.174 | 0.5989 | 0.0553 | 0.8018 | |||
| BT-20 | TNBC | Basal A | Mebendazole | 66.7 | uM | 13579.174 | 0.2130 | -0.7093 | 0.8018 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 0.000171 | uM | 13125.174 | 0.9618 | 0.9212 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 0.000853 | uM | 13125.174 | 0.9075 | 0.8093 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 0.00427 | uM | 13125.174 | 0.9509 | 0.8986 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 0.0213 | uM | 13125.174 | 0.9546 | 0.9063 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 0.107 | uM | 13125.174 | 0.9145 | 0.8237 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 0.533 | uM | 13125.174 | 0.5998 | 0.1798 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 2.67 | uM | 13125.174 | 0.5156 | 0.0091 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 13.3 | uM | 13125.174 | 0.4396 | -0.1439 | 0.9685 | |||
| BT-474 | HER2amp | Luminal | Mebendazole | 66.7 | uM | 13125.174 | 0.3972 | -0.2292 | 0.9685 | |||
| BT-483 | HR+ | Luminal | Mebendazole | 0.000171 | uM | 13130.174 | 0.9607 | 0.8496 | 0.5126 | |||
| BT-483 | HR+ | Luminal | Mebendazole | 0.000853 | uM | 13130.174 | 0.9496 | 0.8081 | 0.5126 | |||
| BT-483 | HR+ | Luminal | Mebendazole | 0.00427 | uM | 13130.174 | 0.9755 | 0.9055 | 0.5126 | |||
| BT-483 | HR+ | Luminal | Mebendazole | 0.0213 | uM | 13130.174 | 0.9669 | 0.8729 | 0.5126 | |||
| BT-483 | HR+ | Luminal | Mebendazole | 0.107 | uM | 13130.174 | 0.9563 | 0.8330 | 0.5126 |